Top Markets
Coin of the day
Lexeo Therapeutics, Inc. Common Stock Lexeo Therapeutics, Inc. Common Stock

Lexeo Therapeutics, Inc. Common Stock

LXEO
Pozycja w akcjach #15139
Lexeo Therapeutics, Inc. is a genetic medicine firm currently in the clinical... Lexeo Therapeutics, Inc. is a genetic medicine firm currently in the clinical development phase, dedicated to addressing both inherited and acquired medical conditions. Its robust pipeline features several gene therapy candidates. These include LX2006, an AAVrh10-based therapy aimed at treating cardiomyopathy linked to Friedreich's ataxia (FA); LX2020, another AAVrh10-based candidate targeting arrhythmogenic cardiomyopathy; LX2021, designed for DSP cardiomyopathy; and LX2022, which focuses on hypertrophic cardiomyopathy (HCM) stemming from TNNI3 mutations. Furthermore, Lexeo is advancing LX1001, an AAVrh10-based gene therapy, alongside LX1020 and LX1021, all intended for individuals homozygous for APOE4. Additionally, LX1004 is under development to treat CLN2 Batten disease. Established in 2017, the company's headquarters are located in New York, New York.
Cena akcji
$4.72
Kapitalizacja rynkowa
$370.28M
Zmiana (1 dzień)
-0.93%
Zmiana (1 rok)
-1.55%
Kraj
US
Handel Lexeo Therapeutics, Inc. Common Stock (LXEO)

Kategoria

Historia stopy dywidendy dla Lexeo Therapeutics, Inc. Common Stock (LXEO)
Stopa dywidendy (TTM) dla Lexeo Therapeutics, Inc. Common Stock (symbol akcji: LXEO) na dzień 2026 wynosi: 0
Średnia stopa dywidendy z ostatnich 5 lat: 0.00%
Historia stopy dywidendy dla Lexeo Therapeutics, Inc. Common Stock (LXEO) od 2026 do 2026
Stopa dywidendy na koniec każdego roku (TTM)
Rok Stopa dywidendy Zmień
Za mało danych dla podanych dat.
Stopy dywidendy (TTM) dla podobnych firm lub konkurencji